Ishida H, Okabe M, Gomi K, Horiuchi R
Pharmaceutical Research Laboratories, Kyowa Hakko Kogyo Co., Ltd.
Gan To Kagaku Ryoho. 1993 Apr;20(5):625-30.
As 5-fluorouracil (5-FU) has been known to show clinically antitumor effects against both breast and stomach carcinomas. We compared the combined effects of medroxyprogesterone acetate (MPA) with 5-FU on the growth of cultured human breast and stomach carcinoma cells. MPA inhibited the growth of estrogen-dependent human breast carcinoma MCF-7 cells at the low concentrations and exhibited an additive effect in combination with 5-FU. MPA also inhibited the growth of human stomach carcinoma MKN-45 cells at relatively high concentrations and exhibited an additive effect in combination with 5-FU. Human stomach carcinoma MKN-28 cells were rather insensitive to MPA, but, an additive combination effect of MPA and 5-FU was observed. These three cell lines were found to have MPA-binding proteins which may be distinct from the nuclear progesterone receptor, suggesting the correlation with growth-inhibitory activity of MPA.
由于已知5-氟尿嘧啶(5-FU)对乳腺癌和胃癌均显示出临床抗肿瘤作用。我们比较了醋酸甲羟孕酮(MPA)与5-FU对培养的人乳腺癌和胃癌细胞生长的联合作用。MPA在低浓度时抑制雌激素依赖性人乳腺癌MCF-7细胞的生长,并与5-FU联合时表现出相加作用。MPA在相对高浓度时也抑制人胃癌MKN-45细胞的生长,并与5-FU联合时表现出相加作用。人胃癌MKN-28细胞对MPA相当不敏感,但观察到MPA与5-FU有相加联合作用。发现这三种细胞系具有MPA结合蛋白,其可能与核孕酮受体不同,提示与MPA的生长抑制活性相关。